Hunan Warner’s Metformin and Empagliflozin Tablets (I) Approved, Deemed to Pass Consistency Evaluation
November 12, 2026
Source: drugdu
27
On the evening of November 10, Hunan Warner Pharmaceutical (688799) announced that it had recently received a Drug Registration Certificate for metformin and empagliflozin tablets (I), issued by the National Medical Products Administration (NMPA).
The product, with approval number H20266500, contains 500 mg of metformin hydrochloride and 5 mg of empagliflozin per tablet. It was approved as a Class 4 chemical drug under the new registration classification and is deemed to have passed the generic quality and efficacy consistency evaluation.
Used alongside diet control and exercise, metformin and empagliflozin tablets (I) are indicated for adults with type 2 diabetes already treated with empagliflozin and metformin hydrochloride, to improve their glycemic control.
Source: http://finance.eastmoney.com/a/202611103927450284.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- enGene to Initiate BLA Submission by Year End and Reports New LEGEND Data in Bladder Cancer November 12, 2026
- CorMedix to Acquire Heron Therapeutics’ Commercial Assets for $145 Million in Cash and Stock November 12, 2026
- MaxCyte to Acquire Akron Bio for $151.8 Million, Expanding Across the Cell Therapy Manufacturing Workflow November 12, 2026
- Revenue increased fourfold, yet 35% of employees were laid off. November 12, 2026
- Johnson & Johnson officially announces major collaboration. November 12, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
